These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38395521)

  • 1. Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.
    Yamagishi A; Ikekubo Y; Mishina M; Ikeda K; Ide S
    J Pharmacol Sci; 2024 Mar; 154(3):203-208. PubMed ID: 38395521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant-relevant concentrations of the ketamine metabolite (2
    Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
    Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
    Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
    Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD
    Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (
    Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
    Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
    Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
    Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
    Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA
    Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine.
    Ide S; Ikekubo Y; Mishina M; Hashimoto K; Ikeda K
    J Pharmacol Sci; 2017 Nov; 135(3):138-140. PubMed ID: 29174627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
    Ju L; Yang J; Zhu T; Liu P; Yang J
    BMC Psychiatry; 2022 Mar; 22(1):182. PubMed ID: 35291971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
    Hashimoto K
    Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
    Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
    Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
    Chou D
    Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.
    Zhang K; Fujita Y; Hashimoto K
    Sci Rep; 2018 Mar; 8(1):4007. PubMed ID: 29507385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
    Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC
    Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.
    Zhang K; Toki H; Fujita Y; Ma M; Chang L; Qu Y; Harada S; Nemoto T; Mizuno-Yasuhira A; Yamaguchi JI; Chaki S; Hashimoto K
    Psychopharmacology (Berl); 2018 Nov; 235(11):3177-3185. PubMed ID: 30215218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex-dependent metabolism of ketamine and (
    Highland JN; Farmer CA; Zanos P; Lovett J; Zarate CA; Moaddel R; Gould TD
    J Psychopharmacol; 2022 Feb; 36(2):170-182. PubMed ID: 34971525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cAMP-dependent protein kinase signaling is required for (
    Riggs LM; Pereira EFR; Thompson SM; Gould TD
    J Neurophysiol; 2024 Jan; 131(1):64-74. PubMed ID: 38050689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
    Xiong Z; Fujita Y; Zhang K; Pu Y; Chang L; Ma M; Chen J; Hashimoto K
    Behav Brain Res; 2019 Aug; 368():111904. PubMed ID: 30980851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
    Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
    Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.